0001662774 2026-05-17 2026-05-17 true 0001662774 8-K/A 2026-05-17 QUINCE THERAPEUTICS, INC. DE 001-38890 90-1024039 611 Gateway Boulevard Suite 273 South San Francisco CA 94080 (415) 910-5717 false false false false Common Stock, par value $0.001 per share QNCX NASDAQ false This Amendment No 1 to the Current Report on Form 8-K (the “Original Filing”) that was originally filed with the Securities and Exchange Commission on May 18, 2026 is being filed solely to replace the press release included as Exhibit 99.2 to the Original Filing, to update the table under the heading “LAM-001 Phase 2a PH Efficacy” to replace 35.3% and 28.1% with -35.3% and -28.1%, respectively. No other changes have been made to the Original Filing.